Irene Mamkin
Pediatric Endocrinology · West Orange, NJNPI 1326210485
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.7% of the total. 2025 is the largest year on record at $8,438, 10.0 times the $845 reported in 2019. Among pediatric endocrinology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $35.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$4K
- Sanofi-aventis U.S. LLC$3K
- Novo Nordisk$859
- AbbVie$763
- Pfizer$572
- Insulet Corporation$472
- plus $4K from 34 others
What the payments were for
- Consulting fees$5,22539%
- Travel & lodging$1,0868%
- Food & beverage$7,13353%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 19 | $3,865 |
| Sanofi-aventis U.S. LLC | 23 | $3,255 |
| Novo Nordisk | 44 | $859 |
| AbbVie | 56 | $763 |
| Pfizer | 22 | $572 |
| Insulet Corporation | 12 | $472 |
| AstraZeneca | 15 | $382 |
| Dexcom, Inc. | 12 | $302 |
| Biomarin Pharmaceutical Inc. | 12 | $271 |
| Lilly USA, LLC | 19 | $259 |
| Ascendis Pharma Endocrinology Inc | 15 | $241 |
| Tolmar, Inc. | 12 | $201 |
| Abbott | 10 | $182 |
| Medtronic(2 entities) | 8 | $148 |
| Tandem Diabetes Care, Inc. | 6 | $145 |
| Kyowa Kirin, Inc. | 8 | $144 |
| Endo Pharmaceuticals Inc. | 10 | $138 |
| Ipsen Biopharmaceuticals, Inc | 8 | $138 |
| Rhythm Pharmaceuticals, Inc. | 8 | $137 |
| Azurity Pharmaceuticals, Inc. | 7 | $119 |
| GSK | 6 | $99 |
| Tolmar Pharmaceuticals, Inc. | 6 | $88 |
| Xeris Pharmaceuticals, Inc. | 5 | $71 |
| IBSA Pharma Inc. | 5 | $71 |
| Endo USA, Inc. | 4 | $69 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| BETA Bionics, Inc. | 2 | $50 |
| Amphastar Pharmaceuticals, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Sandoz | 3 | $42 |
| Zealand Pharma US, Inc. | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 3 | $41 |
| Travere Therapeutics, Inc. | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $20 |
| Vertex | 1 | $18 |
| BD | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Eton Pharmaceuticals, Inc. | 1 | $14 |
| Albireo Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$3,368
- NGENLA$211
- Omnipod$149
- Sogroya$120
- DEXCOM G7 GSS (161)$109
How this compares
$13,456 in reported general payments places this provider in the 90th percentile of 59 pediatric endocrinology providers in New Jersey.
Other pediatric endocrinology in West Orange
- Dennis BrennerWest Orange$39K
- Marianne JacobWest Orange$3K
- Lawrence SilvermanMorristown$492K
- Ahmed KhattabNew Brunswick$70K
- Ian MarshallNew Brunswick$51K
- Eric HuangBasking Ridge$23K
- Elizabeth BurtmanTenafly$10K
- Javier AisenbergHackensack$10K
- Hope-Elizabeth ClennonNewark$8K
- Glenn GormleyBrick$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.